[1]
Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clinical microbiology reviews. 2010 Jan:23(1):160-201. doi: 10.1128/CMR.00037-09. Epub
[PubMed PMID: 20065329]
[2]
Karlović K, Nikolić J, Arapović J. Ceftriaxone treatment of complicated urinary tract infections as a risk factor for enterococcal re-infection and prolonged hospitalization: A 6-year retrospective study. Bosnian journal of basic medical sciences. 2018 Nov 7:18(4):361-366. doi: 10.17305/bjbms.2018.3544. Epub 2018 Nov 7
[PubMed PMID: 29750894]
Level 2 (mid-level) evidence
[5]
Jacobs MR. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles. Expert review of anti-infective therapy. 2005 Jun:3(3):353-60
[PubMed PMID: 15954852]
[6]
Matho A, Mulqueen M, Tanino M, Quidort A, Cheung J, Pollard J, Rodriguez J, Swamy S, Tayler B, Garrison G, Ata A, Sorum P. High-dose versus standard-dose amoxicillin/clavulanate for clinically-diagnosed acute bacterial sinusitis: A randomized clinical trial. PloS one. 2018:13(5):e0196734. doi: 10.1371/journal.pone.0196734. Epub 2018 May 8
[PubMed PMID: 29738561]
Level 1 (high-level) evidence
[7]
Chams S, El Sayegh S, Hamdon M, Kumar S, Tegeltija V. Amoxicillin/clavulanic acid-induced pancreatitis: case report. BMC gastroenterology. 2018 Aug 2:18(1):122. doi: 10.1186/s12876-018-0851-6. Epub 2018 Aug 2
[PubMed PMID: 30071846]
Level 3 (low-level) evidence
[8]
Iravani A, Richard GA. Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid. Antimicrobial agents and chemotherapy. 1982 Oct:22(4):672-7
[PubMed PMID: 7181477]
[9]
deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, Kleiner DE, Bonkovsky HL, Drug-Induced Liver Injury Network (DILIN). Amoxicillin-Clavulanate-Induced Liver Injury. Digestive diseases and sciences. 2016 Aug:61(8):2406-2416. doi: 10.1007/s10620-016-4121-6. Epub 2016 Mar 22
[PubMed PMID: 27003146]
[10]
Crass RL, Pai MP. Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors. Pharmacotherapy. 2019 Feb:39(2):182-195. doi: 10.1002/phar.2210. Epub 2019 Jan 20
[PubMed PMID: 30589457]
[11]
Sembera S, Lammert C, Talwalkar JA, Sanderson SO, Poterucha JJ, Hay JE, Wiesner RH, Gores GJ, Rosen CB, Heimbach JK, Charlton MR. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2012 Jul:18(7):803-10. doi: 10.1002/lt.23424. Epub
[PubMed PMID: 22389256]
[12]
Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert opinion on drug safety. 2014 Jan:13(1):67-81. doi: 10.1517/14740338.2013.828032. Epub 2013 Sep 27
[PubMed PMID: 24073714]
Level 3 (low-level) evidence
[13]
Giordano C, Rivas J, Zervos X. An Update on Treatment of Drug-Induced Liver Injury. Journal of clinical and translational hepatology. 2014 Jun:2(2):74-9. doi: 10.14218/JCTH.2014.00005. Epub 2014 Jun 15
[PubMed PMID: 26356645]